Polypid Ltd (PYPD) Stock Price, Quote & News

Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 4719 5700

Website: www.polypid.com

Address:

18 Hasivim Street, Petah Tikva, Israel

JarvisFlow Nov. 13 at 4:39 PM

Roth Capital updates rating for PolyPid ( $PYPD ) to Buy, target set at 10 → 9.

0 · Reply

PaulWalter Nov. 12 at 1:50 PM

$PYPD I correct myself. It’s not a pos. The products are great, Managemevt is crap. Couldn’t close an envelope.

0 · Reply

WallStWireAds Nov. 12 at 12:32 PM

$PYPD https://caplynx.io/9FgdOH

0 · Reply

PaulWalter Nov. 7 at 5:45 PM

$PYPD This really is a pos.

0 · Reply

lelXYpics Nov. 6 at 6:54 PM

$PYPD Yet another affirmation: https://investors.polypid.com/news-releases/news-release-details/polypids-d-plex100-wins-biotech-breakthrough-award-therapeutics

0 · Reply

Finnish_boy Nov. 4 at 10:41 PM

$PYPD Any catalysts? ;) three in 5 months.. lets goooo!

0 · Reply

Finnish_boy Nov. 4 at 10:37 PM

$PYPD - GLP-1 data this year. - US partner at the start of next year - NDA Q1 - FDA approval Q4 next year - Q1 2027.

2 · Reply

pandodark Nov. 4 at 5:28 AM

$PYPD Big things happening. This is going to be a runner.

0 · Reply

CARTE_BLANCHE_DEVEREAUX Oct. 29 at 5:01 PM

$PYPD New post up, about why I think Biotech is the most interesting sector in the market... And what we can expect to see in the next 24 months. Is TEVA looking over here? https://www.reddit.com/r/TheBlancheRanch/s/TofvyWBigm

1 · Reply

WallStWireAds Oct. 29 at 12:32 PM

$PYPD https://caplynx.io/DOjkape

0 · Reply

PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:30 AM EST - 2 days ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:30 AM EST - 8 days ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Oct 29, 2025, 8:30 AM EDT - 16 days ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Sep 30, 2025, 8:45 AM EDT - 6 weeks ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 17, 2025, 8:44 AM EDT - 2 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 16, 2025, 8:30 AM EDT - 2 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 3, 2025, 8:30 AM EDT - 2 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 2 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Aug 13, 2025, 4:52 PM EDT - 3 months ago

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:30 AM EDT - 3 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 8:00 AM EDT - 3 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Jul 30, 2025, 8:00 AM EDT - 3 months ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 15, 2025, 8:00 AM EDT - 4 months ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jun 16, 2025, 7:20 PM EDT - 5 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 11, 2025, 9:42 AM EDT - 5 months ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 5 months ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 9, 2025, 8:54 AM EDT - 5 months ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 7:30 AM EDT - 5 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 6, 2025, 4:05 PM EDT - 5 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

May 30, 2025, 10:12 AM EDT - 6 months ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 20, 2025, 7:00 AM EDT - 6 months ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 14, 2025, 1:24 PM EDT - 6 months ago

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:00 AM EDT - 6 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 7 months ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 22, 2025, 7:00 AM EDT - 7 months ago

PolyPid to Participate in The Citizens Life Sciences Conference

Mar 11, 2025, 7:00 AM EDT - 8 months ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 3, 2025, 7:00 AM EST - 9 months ago

PolyPid to Participate in the 37th Annual ROTH Conference

Feb 12, 2025, 10:44 AM EST - 9 months ago

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 9 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 30, 2025, 7:00 AM EST - 10 months ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 10 months ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Dec 26, 2024, 10:31 AM EST - 11 months ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

Dec 23, 2024, 7:22 PM EST - 11 months ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 13, 2024, 2:06 PM EST - 1 year ago

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Aug 14, 2024, 1:25 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 8:31 PM EDT - 1 year ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Jul 31, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

Jun 10, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

May 9, 2024, 10:38 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Citizens JMP Life Sciences Conference

Apr 30, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

JarvisFlow Nov. 13 at 4:39 PM

Roth Capital updates rating for PolyPid ( $PYPD ) to Buy, target set at 10 → 9.

0 · Reply

PaulWalter Nov. 12 at 1:50 PM

$PYPD I correct myself. It’s not a pos. The products are great, Managemevt is crap. Couldn’t close an envelope.

0 · Reply

WallStWireAds Nov. 12 at 12:32 PM

$PYPD https://caplynx.io/9FgdOH

0 · Reply

PaulWalter Nov. 7 at 5:45 PM

$PYPD This really is a pos.

0 · Reply

lelXYpics Nov. 6 at 6:54 PM

$PYPD Yet another affirmation: https://investors.polypid.com/news-releases/news-release-details/polypids-d-plex100-wins-biotech-breakthrough-award-therapeutics

0 · Reply

Finnish_boy Nov. 4 at 10:41 PM

$PYPD Any catalysts? ;) three in 5 months.. lets goooo!

0 · Reply

Finnish_boy Nov. 4 at 10:37 PM

$PYPD - GLP-1 data this year. - US partner at the start of next year - NDA Q1 - FDA approval Q4 next year - Q1 2027.

2 · Reply

pandodark Nov. 4 at 5:28 AM

$PYPD Big things happening. This is going to be a runner.

0 · Reply

CARTE_BLANCHE_DEVEREAUX Oct. 29 at 5:01 PM

1 · Reply

WallStWireAds Oct. 29 at 12:32 PM

$PYPD https://caplynx.io/DOjkape

0 · Reply

CARTE_BLANCHE_DEVEREAUX Oct. 28 at 9:12 PM

$ANRO I'm late putting out my ANRO DD. Honestly wasn't expecting such a push into readout. I'll take it though! DD up on $BTAI and one each for $CING and $PYPD coming this week. I've got a backlog of about 2 dozen tickers I'm in, but I'm already looking for new material past that. Send those tickers babes, and check out this post! https://www.reddit.com/r/TheBlancheRanch/s/F1OeFyf4Sk

1 · Reply

ShowMeTheMoney17 Oct. 28 at 8:21 PM

$SOFI $PYPD Amazing how opposite they opened and closed.

0 · Reply

Project_Profit Oct. 28 at 1:36 PM

$PYPD Grinding higher. Not a lot of volume but nobody is dumping their shares here. I think something will be announced soon between PYPD and a partner Such good top line data in a very disruptive tech. A big fish will want to eat this guppy up IMHO

0 · Reply

WallStWireAds Oct. 27 at 12:52 PM

$PYPD https://alphacatalyst.beehiiv.com/p/as-antibiotic-resistance-hits-a-tipping-point-this-company-s-innovative-prevention-technology-stands

0 · Reply

Finnish_boy Oct. 21 at 7:58 AM

$PYPD https://www.clinicalleader.com/doc/how-one-biopharma-company-overcame-trial-failure-0001

0 · Reply

Finnish_boy Oct. 21 at 7:51 AM

$PYPD Bought this.. dirty cheap.. there are some risks but this is exceptionally "risk-free" bio. GLP1-massive potential bonus for $55M market cap company: "I expect that this program, once we have this more robust preclinical data, will be a subject to some sort of a collaboration." And stock is too cheap considering only D-PLEX_100

1 · Reply

WallStWireAds Oct. 12 at 3:39 PM

$PYPD https://thefinanceherald.com/an-overlooked-crisis-in-hospitals-could-be-pharmas-next-great-opportunity/

0 · Reply

CARTE_BLANCHE_DEVEREAUX Oct. 9 at 9:35 PM

$PYPD Easy to accumulate until mid Q1. Not expecting any fireworks til mid 26. I'm super happy at these levels.

1 · Reply

PaulWalter Oct. 9 at 8:54 AM

$PYPD It seems they can‘t get a deal/ partnership over the line. Product should sell itself.

1 · Reply

PaulWalter Oct. 8 at 4:57 PM

$PYPD This is the most boring stock in history.

1 · Reply

Nigoolas Oct. 8 at 3:30 AM

$PYPD very nice entry atm!! BEST stock ever!!

0 · Reply

Stef_DL Oct. 7 at 7:59 PM

$PYPD A temping buy whenever she dips closer to 3. I might need to step in for a little buying 😊.

0 · Reply

Market Cap	56.91M
Revenue (ttm)	0.00
Net Income (ttm)	-29.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.32

Volume	8,400
Avg Vol	72,738
Day's Range	N/A - N/A
Shares Out	15.90M
Stochastic %K	21%
Beta	1.53
Analysts	Strong Sell
Price Target	$12.25